Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 446286-61-9 | MDL No. : | MFCD00483243 |
Formula : | C8H10BrN3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | AKQGPROZPHKDMD-UHFFFAOYSA-N |
M.W : | 228.09 | Pubchem ID : | 6622013 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.5 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 54.37 |
TPSA : | 29.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.38 cm/s |
Log Po/w (iLOGP) : | 2.24 |
Log Po/w (XLOGP3) : | 1.84 |
Log Po/w (WLOGP) : | 1.46 |
Log Po/w (MLOGP) : | 1.49 |
Log Po/w (SILICOS-IT) : | 1.99 |
Consensus Log Po/w : | 1.8 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.72 |
Solubility : | 0.437 mg/ml ; 0.00192 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.07 |
Solubility : | 1.94 mg/ml ; 0.00851 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.96 |
Solubility : | 0.252 mg/ml ; 0.0011 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.77 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
15% | Stage #1: 5-bromo-2-(pyrrolidin-1-yl)pyrimidine With ferrous(II) sulfate heptahydrate; sulfuric acid In water; toluene at -10℃; Stage #2: α-hydroxy-α-(ethoxycarbonyl)ethyl hydroperoxide With acetic acid In water; toluene at -10 - 0℃; for 1.5h; Stage #3: With sodium hydroxide In water; toluene Cooling with ice; regioselective reaction; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | With tetrakis(triphenylphosphine) palladium(0); sodium carbonate In 1,2-dimethoxyethane; water at 75℃; for 6h; Inert atmosphere; | General coupling procedure General procedure: To a solution of the aryl bromide and corresponding aryl boronic acid or aryl boronic acid pinacol ester in the listed solvent mixture were added the listed palladium catalyst and aqueous solution of base (See Table S1). The mixtures were stirred under Ar at 70-90 °C for the stated time. The reaction mixtures were then cooled to room temperature. The products were purified by flash chromatography or by crystallization using the stated solvents. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With copper(l) iodide; palladium diacetate; N-ethyl-N,N-diisopropylamine; tricyclohexylphosphine In N,N-dimethyl-formamide at 60℃; Sealed tube; Inert atmosphere; | 3-((2-(cyclopropylamino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide General procedure: A mixture of 3-ethynyl-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide 8 (192 mg, 0.5 mmol), N-cyclopropyl-5-bromopyrimidin-2-amine9 (107 mg,0.5 mmol), Cu(I)iodide (19mg, 0.1mmol), Pd(OAc)2 (2.2 mg, 0.01 mmol), PCy3 (2.8 mg,0.01 mmol), DIPEA (193 mg, 1.5 mmol), and DMF (3 mL) were added to a sealed tube. The tube was evacuated and backfilled with argon (3 cycles). After stirring at 60°C for 12 h, the reaction mixture was filtered and washed three times with EtOAc. The solvent was removed under vacuum and the resultant crude material was purified by column chromatography to give the title compound 4e (193 mg, yield 75%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: copper(l) iodide; N,N`-dimethylethylenediamine; sodium iodide / 1,3-dioxane / 24 h / 110 °C / Inert atmosphere 2: (S)-4-benzyl-2-(2-(bis(4-methoxy-3,5-dimethylphenyl)phosphanyl)phenyl)-4,5-dihydrooxazole; manganese; chloro-trimethyl-silane; (1,2-dimethoxyethane)dichloronickel(II) / 1,4-dioxane / 16 h / 20 °C / Inert atmosphere; Sealed tube |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: copper(l) iodide; N,N`-dimethylethylenediamine; sodium iodide / 1,3-dioxane / 24 h / 110 °C / Inert atmosphere 2: (S)-4-benzyl-2-(2-(bis(4-methoxy-3,5-dimethylphenyl)phosphanyl)phenyl)-4,5-dihydrooxazole; manganese; chloro-trimethyl-silane; (1,2-dimethoxyethane)dichloronickel(II) / 1,4-dioxane / 16 h / 20 °C / Inert atmosphere; Sealed tube |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
97% | With copper(l) iodide; sodium iodide; N,N`-dimethylethylenediamine In 1,3-dioxane at 110℃; for 24h; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
4% | With potassium <i>tert</i>-butylate; palladium diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl In 1,4-dioxane at 100 - 110℃; for 16h; Inert atmosphere; | 333 Preparation of 2-(5-chloro-2,4-dimethoxyphenyl)-7-(4-(2-pyrrolidin-l-yl)pyrimidin-5-yl)piperazin-l-yl)imidazo[l ,2-a]pyridine 309e (Example 333); A suspension of 2-(5-chloro-2,4-dimethoxyphenyl)-7-(piperazin-1-yl)imidazo[1 ,2-a]pyridine 301 (200 mg, 0.53 mmol), 5-bromo-2-(pyrrolidin- l-yl)pyrimidine (236 mg, 1.00 mmol), B1NAP (33 mg, 0.053 mmol) and KOt-Bu ( 180 mg, 1.6 mmol) in 1,4-dioxane (4.0 mL) was degassed with argon for 15 min. To the suspension was added Pd(OAc)2 ( mg, 0.026 mmol) and the reaction mixture was further degassed with argon for 5 min. The reaction mixture was stirred at 100-1 10 °C for 16 h before it was cooled to room temperature. The reaction mixture was filtered through a pad of celrte, and the filtrate was concentrated to dryness. The residue was purified combi-flash companion (silica gel, CH3OH/CH2CI2) to provide 2-(5-chloro-2, 4-dimethoxyphenyl)-7-(4-(2-(pyrrolidin-l-yl) pyrimidin-5-yl) piperazin-l-yl) imidazo [ 1,2-ajpyridine 309e (Example 333) ( 12 mg, 4%) as an off-white solid. H NMR (300 MHz, DMSO-ifc): δ 8.34 (d, J ------ 7.5 Hz, 1H), 8.24 i s. 2H), 8.17 (s, 1H), 8.04(s, 1H), 6,88 (d, J = 5.4 Hz, 2H), 6.73 (s, I I I). 4.01 (s, 3H), 3.93 (s, M l). 3.46-3.37(iri, 8H), 3.12 (s, 4H), 1.93-1.89 (m, 4H). HPLC (Method 1) 98.4% (AUC), tR ----- 12.25 min. ESI+APCI MS m/z 520,0 [M + H | |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
72% | With bis[2-(diphenylphosphino)phenyl] ether; bis(dibenzylideneacetone)-palladium(0) In toluene at 80℃; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1.1: magnesium; lithium chloride; ethylene dibromide / tetrahydrofuran / 2 h / 20 °C / Inert atmosphere; Sealed tube 1.2: 1 h / 20 °C / Inert atmosphere 2.1: Bathocuproine; nickel(II) acetylacetonate monohydrate; magnesium chloride / 1,4-dioxane / 0.08 h / 23 °C / Inert atmosphere; Sealed tube 2.2: 12 h / 23 °C / Inert atmosphere; Sealed tube |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: 5-bromo-2-(pyrrolidin-1-yl)pyrimidine With magnesium; ethylene dibromide; lithium chloride In tetrahydrofuran at 20℃; for 2h; Inert atmosphere; Sealed tube; Stage #2: zinc dimethoxide In tetrahydrofuran at 20℃; for 1h; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
92.4% | In ethanol at 80℃; | 40.1 Step 1: Preparation of 5-bromo-2-(pyrrolidin-1-yl)pyrimidine (40a) 5-Bromo-2-chloropyrimidine (1.0 g, 5.17 mmol) and tetrahydropyrrole (0.74 g, 10.34 mmol) were dissolved in absolute ethanol (10 mL) at room temperature.The reaction solution was stirred at 80°C overnight, concentrated under reduced pressure, the residue was diluted with water (50 mL), and then extracted with ethyl acetate (3×50 mL). The combined organic phases were washed with saturated brine (50 mL), and anhydrous sodium sulfate Dry, filter, and concentrate the filtrate under reduced pressure to obtain compound 40a (1.09 g, 92.4%) as a white solid. |
88% | With potassium carbonate In acetonitrile at 80℃; for 16h; Inert atmosphere; |
[ 1015241-96-9 ]
1-(5-Bromopyrimidin-2-yl)azepane
Similarity: 0.96
[ 57356-64-6 ]
5-Bromo-2-(piperidin-1-yl)pyrimidine
Similarity: 0.94
[ 1289089-91-3 ]
5-bromo-2-(4-methylpiperidin-1-yl)pyrimidine
Similarity: 0.90
[ 850349-22-3 ]
2-(Azetidin-1-yl)-5-bromopyrimidine
Similarity: 0.89
[ 14001-71-9 ]
5-Bromo-N-butylpyrimidin-2-amine
Similarity: 0.89
[ 914347-70-9 ]
1-(5-Bromopyrimidin-2-yl)-3-pyrrolidinol
Similarity: 0.84
[ 1015241-96-9 ]
1-(5-Bromopyrimidin-2-yl)azepane
Similarity: 0.96
[ 57356-64-6 ]
5-Bromo-2-(piperidin-1-yl)pyrimidine
Similarity: 0.94
[ 1289089-91-3 ]
5-bromo-2-(4-methylpiperidin-1-yl)pyrimidine
Similarity: 0.90
[ 850349-22-3 ]
2-(Azetidin-1-yl)-5-bromopyrimidine
Similarity: 0.89
[ 14001-71-9 ]
5-Bromo-N-butylpyrimidin-2-amine
Similarity: 0.89